Alisertib (MLN8237)

Catalog No.S1133

Molecular Weight(MW): 518.92

Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Phase 3.

Cited by 68 Publications

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cell Stem Cell, 2012, 11(2):179-94

PubMed: 22862944 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(14):4552-4566

PubMed: 30979745 ( click the link to review the publication )

Cell Syst, 2019, 9(1):74-92.e8

PubMed: 31302152 ( click the link to review the publication )

Cell Syst, 2019, 8(2):163-167

PubMed: 30797774 ( click the link to review the publication )

Cell Chem Biol, 2019, 10.1016/j.chembiol.2019.06.003

PubMed: 31257184 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2551-2563

PubMed: 30217967 ( click the link to review the publication )

Mol Cell Proteomics, 2018, 17(12):2434-2447

PubMed: 30217950 ( click the link to review the publication )

Mol Med Rep, 2018, 18(1):1206-1210

PubMed: 29845253 ( click the link to review the publication )

Anticancer Res, 2018, 38(6):3471-3476

PubMed: 29848699 ( click the link to review the publication )

J Neurooncol, 2018, 137(3):481-492

PubMed: 29396807 ( click the link to review the publication )

Clin Cancer Res, 2017, 10.1158/1078-0432

PubMed: 28073841 ( click the link to review the publication )

FASEB J, 2017, 32(2):625-638

PubMed: 28970258 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1934-1941

PubMed: 28522591 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2552-2562

PubMed: 28847989 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(6):670-682

PubMed: 28235899 ( click the link to review the publication )

J Biol Chem, 2017, 292(5):1910-1924

PubMed: 28028179 ( click the link to review the publication )

Am J Transl Res, 2017, 9(3):845-873

PubMed: 28386317 ( click the link to review the publication )

Oncotarget, 2017, 8(34):57047-57057

PubMed: 28915653 ( click the link to review the publication )

Arch Toxicol, 2016, 291(10):4939-54

PubMed: 26404763 ( click the link to review the publication )

Sci Rep, 2016, 6:19567

PubMed: 26777522 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 475(3):251-6

PubMed: 27233613 ( click the link to review the publication )

Mol Med Rep, 2016, 14(1):394-8

PubMed: 27177156 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(2):113-22

PubMed: ( click the link to review the publication )
Mol Cancer, 2015, 14(1):83

PubMed: 25889801 ( click the link to review the publication )

J Cell Sci, 2015, 128(2):364-72

PubMed: ( click the link to review the publication )

Breast Cancer Res Tr, 2015, 149(3):715-26

PubMed: 25667100 ( click the link to review the publication )

Drug Des Devel Ther, 2015, 9:1555-84

PubMed: 25792811 ( click the link to review the publication )

Clin Cancer Res, 2014, 34(5):2269-74

PubMed: 24778030 ( click the link to review the publication )

Oncogene, 2014, 33(27):3550-60

PubMed: 23955083 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1253

PubMed: 24853431 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1177

PubMed: 24743732 ( click the link to review the publication )

Cell Death Dis, 2014, 6:e1595

PubMed: 25590805 ( click the link to review the publication )

Mol Cancer Res, 2014, 12(3):433-9

PubMed: 24336958 ( click the link to review the publication )

Biochim Biophys Acta, 2014, 1843(11):2719-2729

PubMed: 25090971 ( click the link to review the publication )

J Transl Med, 2014, 12(1):200

PubMed: 25082261 ( click the link to review the publication )

Mol Carcinog, 2014, 10.1002/mc.22223

PubMed: 25284017 ( click the link to review the publication )

FEBS Lett, 2014, 588(14):2198-205

PubMed: 24857377 ( click the link to review the publication )

Chembiochem, 2014, 15(3):443-50

PubMed: 24403173 ( click the link to review the publication )

PLoS One, 2014, 9(3):e92402

PubMed: 24642638 ( click the link to review the publication )

PLoS One, 2014, 9(12):e116048

PubMed: 25545367 ( click the link to review the publication )

PLoS One, 2014, 9(7):e101222

PubMed: 24983972 ( click the link to review the publication )

PLoS One, 2014, 9(9):e108758

PubMed: 25268132 ( click the link to review the publication )

PLoS One, 2014, 9(7):e102741

PubMed: 25048812 ( click the link to review the publication )

PLoS One, 2014,

PubMed: ( click the link to review the publication )

Neurosci Lett, 2014, 583:199-204

PubMed: 25263789 ( click the link to review the publication )

Nat Commun, 2013, 4:2656

PubMed: 24141283 ( click the link to review the publication )

EMBO Mol Med, 2013, 5(1):149-66

PubMed: 23180582 ( click the link to review the publication )
Leukemia, 2013, 27(3):560-8

PubMed: 22940834 ( click the link to review the publication )

Cancer Res, 2013, 73(20):6310-22

PubMed: 24067506 ( click the link to review the publication )

Int J Cancer, 2013, 135(3):751-62

PubMed: 24382688 ( click the link to review the publication )

Oral Oncol, 2013, 49(6):551-9

PubMed: 23481312 ( click the link to review the publication )

ACS Chem Biol, 2013, 8(7):1451-9

PubMed: 23597309 ( click the link to review the publication )

J Cell Sci, 2013, 126(Pt 6):1355-65

PubMed: 23345402 ( click the link to review the publication )

Biochim Biophys Acta, 2013, 1833(10):2220-32

PubMed: 23707954 ( click the link to review the publication )

J Biol Chem, 2013, 289(1):74-88

PubMed: 24273164 ( click the link to review the publication )

PLoS One, 2013, 8(9):e73548

PubMed: 24019927 ( click the link to review the publication )

J Biol Chem, 2012, 287(33):27670-81

PubMed: 22753416 ( click the link to review the publication )

Breast Cancer Res Tr, 2012, 135(2):433-44

PubMed: 22825030 ( click the link to review the publication )

Cell Cycle, 2012, 11(2):296-309

PubMed: 22214762 ( click the link to review the publication )

Cell Cycle, 2012, 11(13):2567-77

PubMed: 22722494 ( click the link to review the publication )

PLoS One, 2012, 7(2):e30734

PubMed: 22359551 ( click the link to review the publication )

EMBO J, 2011, 30(5):906-19

PubMed: 21297582 ( click the link to review the publication )

Mol Cancer, 2011, 10:131

PubMed: 22011530 ( click the link to review the publication )

J Cell Biol, 2010, 191(7):1315-32

PubMed: 21187329 ( click the link to review the publication )

EMBO Rep, 2010, 11(12):977-84

PubMed: 21072059 ( click the link to review the publication )

ACS Chem Biol, 2010, 5(6):563-76

PubMed: 20426425 ( click the link to review the publication )

Expert Opin Emerg Dr, 2010, 15(4):615-34

PubMed: 20690888 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Aurora Kinase Inhibitors

Biological Activity

Description

Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Phase 3.

Features

First orally available inhibitor of Aurora A.

Targets

Aurora A ^[1]
(Cell-free assay)

1.2 nM

In vitro

MLN8237 shows >200-fold higher selectivity for Aurora A than the structurally related Aurora B with an IC50 of 396.5 nM, and does not have any significant activity against 205 other kinases. ^[1] MLN8237 (0.5 μM) treatment inhibits the phosphorylation of Aurora A in MM1.S and OPM1 cells, without affecting the Aurora B mediated histone H3 phosphorylation. MLN8237 significantly inhibits cell proliferation in multiple myeloma (MM) cell lines with IC50 values of 0.003-1.71 μM. MLN8237 displays more potent anti-proliferation activity against primary MM cells and MM cell lines in the presence of BM stroma cells, as well as IL-6 and IGF-1 than against MM cells alone. MLN8237 (0.5 μM) induces 2- to 6-fold increase in G2/M phase in primary MM cells and cell lines, as well as significant apoptosis and senescence, involving the up-regulation of p53, p21 and p27, as well as PARP, caspase 3, and caspase 9 cleavage. In addition, MLN8237 shows strong synergistic anti-MM effect with dexamethasone, as well as additive effect with doxorubicin and bortezomib. ^[2] MLN8237 (0.5 μM) treatment causes the inhibition of colony formation of FLO-1, OE19, and OE33 esophageal adenocarinoma cell lines, and induces a significant increase in the percentage of polyploid cells, and subsequently an increase in the percentage of cells in the sub-G1 phase, which can be further enhanced in combination with cisplatin (2.5 μM), involving the higher induction of TAp73β, PUMA, NOXA, cleaved caspase-3, and cleaved PARP as compared with a single-agent treatment. ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HCT116	M2K4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkHmNE42KM7:TR?=	MVO3NkBp	M2DmPWROW09?	M3nDfWlEPTB;MD6wOEDPxE1?	MWiyOlE{PjZ6NB?=
LS174T	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn;oNE42KM7:TR?=	NITNb2I4OiCq	M2fLbmROW09?	NYrROWU5UUN3ME2wMlA2KM7:TR?=	M322WVI3OTN4Nki0
T84	M4nZ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1nNWVAvPSEQvF2=	MnXsO\|IhcA>?	Mmm5SG1UVw>?	MUnJR\|UxRTBwMEmg{txO	M2XCT\|I3OTN4Nki0
LS180	NWr0UnlqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{\TV\|AvPSEQvF2=	NVewb2dCPzJiaB?=	MlfGSG1UVw>?	NV7IV\|B3UUN3ME2xJO69VQ>?	NUDCc41iOjZzM{[2PFQ>
SW948	NGjOU4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWXyXW1QOC53IN88US=>	MUW3NkBp	NGO3[oRFVVOR	NVLDPFJqUUN3ME2xJO69VQ>?	M1rhNFI3OTN4Nki0
HCT15	NEDMdFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVWwMlUh\|ryP	NV:1TY16PzJiaB?=	Mmn1SG1UVw>?	MoC5TWM2ODxyLkSg{txO	MXqyOlE{PjZ6NB?=
DLD-1	M3XkPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{LOXVAvPSEQvF2=	NXzub5ozPzJiaB?=	MYTEUXNQ	MWPJR\|UxRDBwODFOwG0>	MYKyOlE{PjZ6NB?=
MIP-101	M2LYRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1XQ[lAvPSEQvF2=	MkXMO\|IhcA>?	NGLGTFZFVVOR	MmjhTWM2OD1zIN88US=>	MWGyOlE{PjZ6NB?=
SNU1544	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHLxZ\|YxNjVizszN	NIfYXZo4OiCq	NGnIe49FVVOR	NWfUTWp6UUN3ME2xJO69VQ>?	NGjXRXgzPjF\|Nk[4OC=>
OCI-Ly10	M3PseWN6fG:2b4jpZ{BCe3OjeR?=		MUm3NkBp	MVfEUXNQ	NWjGPYxSUUN3ME2wMlA2QCEQvF2=	M4jQUVI2QDd6M{Ox
SU-DHL2	MofyR5l1d3SxeHnjJGF{e2G7		NX3TbJZjPzJiaB?=	NWDJcGprTE2VTx?=	M3XBc2lEPTB;MD6wNUDPxE1?	M2r1TlI2QDd6M{Ox
OCI-LY7	M2DRdWN6fG:2b4jpZ{BCe3OjeR?=		NX\CWm1kPzJiaB?=	MmqwSG1UVw>?	NFrae3VKSzVyPUCuNFgyKM7:TR?=	MXiyOVg4QDN\|MR?=
SU-DHL6	NI\EfJNEgXSxdH;4bYMhSXO\|YYm=		MlnXO\|IhcA>?	NYK3fHpxTE2VTx?=	MYfJR\|UxRTBwNEiyJO69VQ>?	NX\jSpN7OjV6N{izN\|E>
Jeko-1	MnjWR5l1d3SxeHnjJGF{e2G7		NHHLT3Q4OiCq	MVLEUXNQ	NIDrdo1KSzVyPUCuNFI6KM7:TR?=	M1H4flI2QDd6M{Ox
JVM-2	Ml:1R5l1d3SxeHnjJGF{e2G7		M2\LbVczKGh?	MkDzSG1UVw>?	M1rlcGlEPTB;MD6wNUDPxE1?	Mmi3NlU5Pzh\|M{G=
Rec-1	M1PafWN6fG:2b4jpZ{BCe3OjeR?=		NGjXcGc4OiCq	MlewSG1UVw>?	MXzJR\|UxRTBwMEi3JO69VQ>?	MljhNlU5Pzh\|M{G=
Z-138	NX[2OWFJS3m2b4TvfIlkKEG\|c3H5		MnzxO\|IhcA>?	NXjo[IRUTE2VTx?=	Mmj6TWM2OD1yLkCxN{DPxE1?	MX:yOVg4QDN\|MR?=
H9	MlHDR5l1d3SxeHnjJGF{e2G7		MUK3NkBp	NYX5bJdLTE2VTx?=	M{C1S2lEPTB;MD62JO69VQ>?	Mmi1NlU5Pzh\|M{G=
HH	NG\Kb2hEgXSxdH;4bYMhSXO\|YYm=		MVS3NkBp	M3npd2ROW09?	Mk\tTWM2OD1yLkeg{txO	NUn0NlV5OjV6N{izN\|E>
DND41	MknhR5l1d3SxeHnjJGF{e2G7		NIrXO5c4OiCq	NIrqN41FVVOR	NYSyWIFEUUN3ME2wMlEh\|ryP	MWKyOVg4QDN\|MR?=
CCL119	NXvZXJdQS3m2b4TvfIlkKEG\|c3H5		M4PVe\|czKGh?	M37VcGROW09?	MV3JR\|UxRTBwME[yJO69VQ>?	NYrwSVZROjV6N{izN\|E>
J.Cam 1.6	M1XWSWN6fG:2b4jpZ{BCe3OjeR?=		MmrsO\|IhcA>?	Mn;tSG1UVw>?	MlTLTWM2OD1yLkGwOUDPxE1?	NIPseJUzPTh5OEOzNS=>
Sup-T1	NH73cZBEgXSxdH;4bYMhSXO\|YYm=		NHXwW2g4OiCq	MnPMSG1UVw>?	NHTJOpJKSzVyPUKuNVQzKM7:TR?=	MlzYNlU5Pzh\|M{G=
Tib 152	NWe3Xop1S3m2b4TvfIlkKEG\|c3H5		M17NSFczKGh?	NWPaSZN1TE2VTx?=	M2nWSmlEPTB;MD64JO69VQ>?	M1r2bFI2QDd6M{Ox
MCF7	MkD0SpVv[3Srb36gRZN{[Xl?	MlP4OUDPxE1?	M33nPFI1KGh?	M{D2fmROW09?	NYnUVpYxUW6mdXPld{BIOi:PIHHydoV{fA>?	M2XaT\|I2QDN2NECx
MDA-MB-231	NGLOSVdHfW6ldHnvckBCe3OjeR?=	NVniflVPPSEQvF2=	MoWyNlQhcA>?	M1LkRWROW09?	NHzyfYdKdmS3Y3XzJGc{N01iYYLy[ZN1	MWKyOVg{PDRyMR?=
MCF7	NXzYTIU4TnWwY4Tpc44hSXO\|YYm=	MlewOUDPxE1?	MWWyOEBp	MWLEUXNQ	MWDE[YNz\WG\|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZiQ1TLNU9ETEN{	NEHXcnozPTh\|NESwNS=>
MCF7	NU\U[WM3TnWwY4Tpc44hSXO\|YYm=	NF7XTJk2KM7:TR?=	MmfVNlQhcA>?	MlPNSG1UVw>?	M2qwWWRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDDSGsz	NH7DTXozPTh\|NESwNS=>
MCF7	NYPLNIZ5TnWwY4Tpc44hSXO\|YYm=	MkPNOUDPxE1?	NFL5U4MzPCCq	NFm4W2hFVVOR	Mnj1SIVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIHP5Z4xqdiCEMR?=	NWi1WHdFOjV6M{S0NFE>
MCF7	NGLRfHRHfW6ldHnvckBCe3OjeR?=	NULXOGNwPSEQvF2=	MV:yOEBp	Ml:0SG1UVw>?	MkW3TY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIICyNUBY[WZzL1PpdFE>	M1uyclI2QDN2NECx
MCF7	NVXXTpZNTnWwY4Tpc44hSXO\|YYm=	MkDPOUDPxE1?	NU\SepBnOjRiaB?=	M{DvSmROW09?	NWPRTlVFUW6lcnXhd4V{KHSqZTDlfJBz\XO\|aX;uJIxmfmWuIH;mJJAzPyCNaYCx	NY\1cZNFOjV6M{S0NFE>
MDA-MB-231	MVfGeY5kfGmxbjDBd5NigQ>?	NWDkNIRTPSEQvF2=	NFLnfpMzPCCq	MWXEUXNQ	NIrTNGRF\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gR2RMOS:FRFOy	MmPyNlU5OzR2MEG=
MDA-MB-231	M3u5NWZ2dmO2aX;uJGF{e2G7	M1vsVVEh\|ryP	NV[0fIRlOjRiaB?=	MXvEUXNQ	NHzVRZNKdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gR2RMOg>?	NWXjd25oOjV6M{S0NFE>
MDA-MB-231	NXi4doc2TnWwY4Tpc44hSXO\|YYm=	NE[3[242KM7:TR?=	MX6yOEBp	NUnQd5hzTE2VTx?=	M4XEOGRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDjfYNtcW5iQkG=	MUmyOVg{PDRyMR?=
MDA-MB-231	MoPzSpVv[3Srb36gRZN{[Xl?	M2rzTVUh\|ryP	NUHyZlF5OjRiaB?=	NFfB[GJFVVOR	NWTuXoxJUW6lcnXhd4V{KHSqZTDlfJBz\XO\|aX;uJIxmfmWuIH;mJJAzOSCZYX[xM2NqeDF?	M2C5ZVI2QDN2NECx
MDA-MB-231	NXvqdpNFTnWwY4Tpc44hSXO\|YYm=	MmPQOUDPxE1?	Mki3NlQhcA>?	Mn3TSG1UVw>?	M2rTe2lv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDwNlchU2myMR?=	NFrEUIozPTh\|NESwNS=>
MDA-MB-231	M3TpU2Z2dmO2aX;uJGF{e2G7	NIS4XXE2KM7:TR?=	MXOyOEBp	NHfFVWRFVVOR	M4XyNGlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDwOVM>	NU\1dXNMOjV6M{S0NFE>
MCF7	MoWwRZBweHSxc3nzJGF{e2G7	MkXOOUDPxE1?	M2HObVI1KGh?	M2\oSWROW09?	MWLJcoR2[2W\|IHHwc5B1d3SrYzDk[YF1cA>?	NXjxSItOOjV6M{S0NFE>
MDA-MB-231	M1zpVGFxd3C2b4Ppd{BCe3OjeR?=	NIniUHY2KM7:TR?=	NIrFbY0zPCCq	NHzOboRFVVOR	NIjNdnhKdmS3Y3XzJIFxd3C2b4TpZ{Bl\WG2aB?=	MonMNlU5OzR2MEG=
MCF7	M4XWfGZ2dmO2aX;uJGF{e2G7	MV:xJO69VQ>?	Ml;YO\|IhcA>?	Mn3KSG1UVw>?	M2nWeGlv\HWlZYOgZZV1d3CqYXfpZ{Bl\WG2aB?=	MUCyOVg{PDRyMR?=
MDA-MB-231	NEnKUI5HfW6ldHnvckBCe3OjeR?=	M1\4[lEh\|ryP	M4XnSFczKGh?	MoP2SG1UVw>?	M2fmSGlv\HWlZYOgZZV1d3CqYXfpZ{Bl\WG2aB?=	M3[0WFI2QDN2NECx
U-2 OS	MlfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXP5dHltPTBizszN	NVXx[plsOjRiaB?=	NXe5ZnRrTE2VTx?=	NX76[IM{UUN3ME2xOk43KM7:TR?=	MnfFNlU4QTJ6MUG=
MG-63	MoPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXS1NEDPxE1?	MWiyOEBp	M1jPfGROW09?	M{TIW2lEPTB;OT61JO69VQ>?	MkWxNlU4QTJ6MUG=
U-2 OS	MmnCRZBweHSxc3nzJGF{e2G7	M{nTe\|Uh\|ryP	M2rOW\|I1KGh?	NVPicI5yTE2VTx?=	MkDaTY5lfWOnczDhdI9xfG:2aXOgZ4VtdCCmZXH0bC=>	MVeyOVc6OjhzMR?=
MG-63	NIr4S3ZCeG:ydH;zbZMhSXO\|YYm=	M4TrU\|Uh\|ryP	M4f6[\|I1KGh?	MXjEUXNQ	NVP6NZRUUW6mdXPld{BieG:ydH;0bYMh[2WubDDk[YF1cA>?	M1LqeVI2Pzl{OEGx
U-2 OS	NYDLU2ZnTnWwY4Tpc44hSXO\|YYm=	Mn[wOUDPxE1?	NFvBV2IzPCCq	MWPEUXNQ	NGDXPJFRem:vb4Tld{BifXSxcHjh[4lkKGOnbHyg[IVifGh?	MXOyOVc6OjhzMR?=
MG-63	NHnGUZFHfW6ldHnvckBCe3OjeR?=	MVK1JO69VQ>?	MknlNlQhcA>?	NHLhWItFVVOR	NHnFPHVRem:vb4Tld{BifXSxcHjh[4lkKGOnbHyg[IVifGh?	M2XmeFI2Pzl{OEGx
PANC-1	NITxNWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVm1NEDPxE1?	M{jMe\|I1KGh?	NGLM[3lFVVOR	M2\jc2lEPTB;Nz6xJO69VQ>?	M4XC[lI2PjN{MkK1
BxPC-3	NW\Mc3N[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4nPdFUxKM7:TR?=	NFm1cpQzPCCq	Ml\RSG1UVw>?	MW\JR\|UxRTZwODFOwG0>	M2nUXVI2PjN{MkK1
PANC-1	NX7yOpNsTnWwY4Tpc44hSXO\|YYm=	M2jJO\|Uh\|ryP	NIfoZXczPCCq	NILp[49FVVOR	MXzJcoR2[2W\|IHPlcIwh[3mlbHWgZZJz\XO2IHnuJGczN01icHjhd4U>	NFvy[pozPTZ\|MkKyOS=>
BxPC-3	M2T6eWZ2dmO2aX;uJGF{e2G7	MXK1JO69VQ>?	MmDLNlQhcA>?	M2[2dWROW09?	NFXiOY9KdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIlvKEd{L12gdIhie2V?	NWjTeWh[OjV4M{KyNlU>
PANC-1	MXjGeY5kfGmxbjDBd5NigQ>?	Mmm2OUDPxE1?	M4jIXVI1KGh?	M3nkPWROW09?	M1TG[2lv\HWlZYOgZZV1d3CqYXfpZ{Bk\WyuIHTlZZRp	MWiyOVY{OjJ{NR?=
BxPC-3	NHrROWlHfW6ldHnvckBCe3OjeR?=	NGL4OIQ2KM7:TR?=	NUnNTlh5OjRiaB?=	MUfEUXNQ	NY[2OGh6UW6mdXPld{BifXSxcHjh[4lkKGOnbHyg[IVifGh?	M1zLb\|I2PjN{MkK1
SKOV3	NGD2U2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUSzSJpMOTByIN88US=>	NEfa[GUzPCCq	M{XZXWROW09?	NUHpUIFpUUN3ME2yNE41QCEQvF2=	M4\rSVI2PjJ2N{Ww
OVCAR4	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYf6[olpOTByIN88US=>	MUKyOEBp	MW\EUXNQ	MXnJR\|UxRTJ{LkGzJO69VQ>?	M2\relI2PjJ2N{Ww
SKOV3	M2\nRWZ2dmO2aX;uJGF{e2G7	NX;ZXJBmPSEQvF2=	M3T5UFczKGh?	NGrjR4pFVVOR	NHTYPZdKdmS3Y3XzJGczN01iYYLy[ZN1	MU[yOVYzPDd3MB?=
OVCAR4	M2iwU2Z2dmO2aX;uJGF{e2G7	Mlu1OUDPxE1?	M3fHTVczKGh?	MVHEUXNQ	NVzBdm85UW6mdXPld{BIOi:PIHHydoV{fA>?	MlvyNlU3OjR5NUC=
SKOV3	NXz2PGZZSXCxcITvd4l{KEG\|c3H5	M2O4[FUh\|ryP	NH36T3czPCCq	NVX2dGQyTE2VTx?=	M3PkXmlv\HWlZYOgZZBweHSxc3nz	NIO2WYYzPTZ{NEe1NC=>
OVCAR4	M3qyRWFxd3C2b4Ppd{BCe3OjeR?=	MVu1JO69VQ>?	MlvaNlQhcA>?	MWDEUXNQ	M1zhTmlv\HWlZYOgZZBweHSxc3nz	MUOyOVYzPDd3MB?=
AGS	M13PZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NITwNYIzPSEQvF2=	MYCyOEBp	NHv0T4tFVVOR	M3fBUWlEPTB;MUmuNFkh\|ryP	NIjLZ5YzPTZyOUmyNy=>
NCI-N78	NVjWd4pZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF:zem0zPSEQvF2=	MknpNlQhcA>?	NXrCc\|dtTE2VTx?=	M2HrU2lEPTB;Mk[uN\|Mh\|ryP	NVj4VI5NOjV4MEm5NlM>
AGS	NHXuN29CeG:ydH;zbZMhSXO\|YYm=	Mmi3OUDPxE1?	NH\hfnQzPCCq	M4LLSWROW09?	NXLuWndSUW6mdXPld{BieG:ydH;zbZM>	M1:zXFI2PjB7OUKz
NCI-N78	NG\seFBCeG:ydH;zbZMhSXO\|YYm=	NE\CcHM2KM7:TR?=	MnrlNlQhcA>?	NXHYUnFOTE2VTx?=	M3[4Xmlv\HWlZYOgZZBweHSxc3nz	M1z2d\|I2PjB7OUKz
AGS	MYPGeY5kfGmxbjDBd5NigQ>?	MV61JO69VQ>?	NFvXT4kzPCCq	NVLa[FRPTE2VTx?=	MXTJcoR2[2W\|IITo[UBifXSxcHjh[5k>	MY[yOVYxQTl{Mx?=
NCI-N78	MVXGeY5kfGmxbjDBd5NigQ>?	NVHWdG1VPSEQvF2=	NYryU2JxOjRiaB?=	MYjEUXNQ	Mm[wTY5lfWOnczD0bIUh[XW2b4DoZYd6	MmPiNlU3ODl7MkO=
HSC-3	M3zze2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NULtOoNbOSEQvF2=	MYq0PEBp		MlLYTWM2OD1yLkW0JO69VQ>?	Mle3NlU{PjZzNEO=
GB30	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NET4fWQyKM7:TR?=	NFr3SHg4KGR?	M3m4XWROW09?	MnPSTWM2OD1yLkCxNUDPxE1?	M4q0dVI2OTB4NEK4
GB9	NHPQWoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHHNNXIyKM7:TR?=	NGHSbGc4KGR?	M{nxdmROW09?	M1mwbmlEPTB;MD6wNlQh\|ryP	Ml3mNlUyODZ2Mki=
GB169	NVzGW3k2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXK5cWdZOSEQvF2=	MV63JIQ>	M1XV[GROW09?	NV3wNGxwUUN3ME2wMlA{OiEQvF2=	NFLtT5QzPTFyNkSyPC=>
T24	NUHSZoZNTnWwY4Tpc44hSXO\|YYm=	M4DXNlEh\|ryP	NFXxOXY1QCCq	NXu4NVB7TE2VTx?=	NGW4SFJKdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0	M2HBOlI{PDB\|NkOz
RT4	NGLObWNHfW6ldHnvckBCe3OjeR?=	MXexJO69VQ>?	MVe0PEBp	NGPwRVdFVVOR	MUfJcoR2[2W\|IHPlcIwh[3mlbHWgZZJz\XO2	NWCydngzOjN2MEO2N\|M>
UM-UC-3	NXvWeZM6TnWwY4Tpc44hSXO\|YYm=	NGn6TmQyKM7:TR?=	NXP4PVRbPDhiaB?=	M3fiTGROW09?	NIfRW5lKdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0	M3XUTFI{PDB\|NkOz
T24	M4PYVmFxd3C2b4Ppd{BCe3OjeR?=	NXLDZpFDOy5zNjFOwG0>	MXy5OkBp	NFG0eFRFVVOR	M1TnTmlEPTB;MD6wN\|A3KM7:TR?=	NHLNZ\|EzOzRyM{[zNy=>
RT4	NYjxfHVsSXCxcITvd4l{KEG\|c3H5	NYKzNII4Oy5zNjFOwG0>	MVu5OkBp	M2rMd2ROW09?	Ml2wTWM2OD1yLkGxPVgh\|ryP	M1;XelI{PDB\|NkOz
UM-UC-3	NW\rRlNoSXCxcITvd4l{KEG\|c3H5	NWHxZYtzOy5zNjFOwG0>	MonnPVYhcA>?	NFP1NYRFVVOR	M1jhdWlEPTB;MD6wOFQ6KM7:TR?=	MWOyN\|QxOzZ\|Mx?=
OVCAR-5	MnzxSpVv[3Srb36gRZN{[Xl?	Mo\LOVAhdk1?			MUXJcohq[mm2czDj[YxtKG2rZ4LheIlwdg>?	M{W2TFI{OzN2M{K3
SKOV3ip2	MkfKSpVv[3Srb36gRZN{[Xl?	NH7TVpc2OCCwTR?=			MX;Jcohq[mm2czDj[YxtKG2rZ4LheIlwdg>?	MorSNlM{OzR\|Mke=
S462	Ml:xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnWxNVAxKM7:TR?=	NFv4UYU4OiCq	Mnq5SG1UVw>?	NVXWS4VnSXS2ZX71ZZRmeyClZXzsJIdzd3e2aB?=	MXeyN\|MzQDFzNB?=
2884	M{Lme2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MorVNVAxKM7:TR?=	MVS3NkBp	M4jqXmROW09?	MUPBeJRmdnWjdHXzJINmdGxiZ4Lve5Rp	NHLJdHYzOzN{OEGxOC=>
2885	NXfTUG44T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXfyPJFIOTByIN88US=>	NF\FU2Y4OiCq	M{PrbGROW09?	M1vZR2F1fGWwdXH0[ZMh[2WubDDndo94fGh?	M3PpZ\|I{OzJ6MUG0
CRL-2396	MlewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1PwVFExOCEQvF2=		NIrCR3F4[XSnch?=	NIfxdplKSzVyPUCuNFkzKM7:TR?=	NUnIc2VGOjNzNUO1NlQ>
TIB-48	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MY[xNFAh\|ryP		NWH5N5V6f2G2ZYK=	MXHJR\|UxRTBwMEi4JO69VQ>?	NY\EVZV6OjNzNUO1NlQ>
CRL-2396	NEL1UopEgXSxdH;4bYMhSXO\|YYm=	MWqxJO69VQ>?	M3fGSFQ5KGh?	MYD3ZZRmeg>?	M{\Rbmlv\HWlZYOgZZBweHSxc3nz	MXqyN\|E2OzV{NB?=
TIB-48	NFPIclFEgXSxdH;4bYMhSXO\|YYm=	NXzJe\|hrOSEQvF2=	M2HNTlQ5KGh?	MnHNe4F1\XJ?	MVnJcoR2[2W\|IHHwc5B1d3Orcx?=	NFLJbo4zOzF3M{WyOC=>
AGS	M1PYWmN6fG:2b4jpZ{BCe3OjeR?=	NIOzU3QxNjVizszN	NFrXSIozPCCq	MX;EUXNQ	NGrLe45F\WO{ZXHz[ZMh[2WubDDzeZJ3cX[jbB?=	M2e0PVIzQTd{NkGx
FLO-1	M{nP[WN6fG:2b4jpZ{BCe3OjeR?=	NF3XSZoxNjVizszN	NYSxO2M{OjRiaB?=	MkPCSG1UVw>?	MYPE[YNz\WG\|ZYOgZ4VtdCC\|dYL2bZZidA>?	NIfvTHUzOjl5Mk[xNS=>
OE33	MkK0R5l1d3SxeHnjJGF{e2G7	NG\LNXUxNjVizszN	MkHvNlQhcA>?	NXm3[ZNbTE2VTx?=	Mk\zSIVkemWjc3XzJINmdGxic4Xyeol3[Wx?	MonDNlI6PzJ4MUG=
SKLMS	MkjQR5l1d3SxeHnjJGF{e2G7	MVS3OUBvVQ>?	NXTMdVJXQTZiaB?=		M{nkR2lv\HWlZYOgZZBweHSxc3nz	MkfnNlI5OjF7OUe=
Leio285	MlnZR5l1d3SxeHnjJGF{e2G7	Mnm4O\|Uhdk1?	MnnEPVYhcA>?		NITlUm1KdmS3Y3XzJIFxd3C2b4Ppdy=>	M1rKeVIzQDJzOUm3
Mes-Sa	NH;mXoVEgXSxdH;4bYMhSXO\|YYm=	NYe2W45GPzVibl2=	Mm\5PVYhcA>?		NFiwWGJKdmS3Y3XzJIFxd3C2b4Ppdy=>	MnnaNlI5OjF7OUe=
DAOY	NXKwfJFkS3m2b4TvfIlkKEG\|c3H5	NIXsSlAyOCEQvF2=	MWe3NkBp	NUTROZVoTE2VTx?=	MYjJR\|UxRTBwMESg{txO	MkDDNlI3Pjl\|M{W=
IMR32	NX\qXINuS3m2b4TvfIlkKEG\|c3H5	M13YRlExKM7:TR?=	MVG3NkBp	NIDFcWhFVVOR	M2X5cWlEPTB;MD6wN{DPxE1?	NFrMTVEzOjZ4OUOzOS=>
Molt-4	NXnSN3VNS3m2b4TvfIlkKEG\|c3H5	NX\KTIdNOTBizszN	M{HjWlczKGh?	NGPJU4tFVVOR	M2LvcGlEPTB;MD6wNkDPxE1?	M2T2UVIzPjZ7M{O1
MOLM-13	MmW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXGzJO69VQ>?	NXzFd\|hGPzJiaB?=		MXzEbY1qdmm\|aHXzJINmdGxidnnhZoltcXS7	MlLLNlI1QDh{NEm=
HL-60	NFPh[ZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGfJbmk{KM7:TR?=	NFHlbIw4OiCq		MorKSIlucW6rc3jld{Bk\WyuII\pZYJqdGm2eR?=	MU[yNlQ5QDJ2OR?=
MV4-11	M17Cd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3O1R\|Mh\|ryP	MV63NkBp		MYDEbY1qdmm\|aHXzJINmdGxidnnhZoltcXS7	NH[wN\|czOjR6OEK0PS=>
SKM-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF[5NXc{KM7:TR?=	MYW3NkBp		NHLHUXlFcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5	M121cFIzPDh6MkS5
SH2	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3nzflMh\|ryP	NWToeodEPzJiaB?=		NIi5V3NFcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5	NX3ieoRUOjJ2OEiyOFk>
NOMO-1	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4DRSlMh\|ryP	M{nRNlczKGh?		NXLING15TGmvaX7pd4hmeyClZXzsJJZq[WKrbHn0fS=>	NVXZRmpUOjJ2OEiyOFk>
OCL-AML2	NF\3ZlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWK5XZhrOyEQvF2=	MUO3NkBp		NV:zXGV3TGmvaX7pd4hmeyClZXzsJJZq[WKrbHn0fS=>	MViyNlQ5QDJ2OR?=
PL-21	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWWzJO69VQ>?	NH\DXGU4OiCq		NEDyPHZFcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5	MnTINlI1QDh{NEm=
KG-1	NV:5S2U{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4q1[\|Mh\|ryP	MVi3NkBp		M4DXUGRqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm=	M2PBfFIzPDh6MkS5
A172	NU[ybYlWS3m2b4TvfIlkKEG\|c3H5	NVPhXXZ4OTByIN88US=>	MUOyOEBp	MkHISG1UVw>?	MV;JR\|UxRTBwMUKwJO69VQ>?	M37Oe\|IzOjd2M{m5
U87	MmnQR5l1d3SxeHnjJGF{e2G7	MVWxNFAh\|ryP	NH\Z[lkzPCCq	MnXzSG1UVw>?	NUDUWXFYUUN3ME2wMlExPSEQvF2=	M2Txb\|IzOjd2M{m5
U251	NXW1N2xDS3m2b4TvfIlkKEG\|c3H5	NXG3[pVKOTByIN88US=>	MkTINlQhcA>?	MU\EUXNQ	NFq0OW1KSzVyPUCuNVAxKM7:TR?=	Moi1NlIzPzR\|OUm=
T98	MnPWR5l1d3SxeHnjJGF{e2G7	M3rLbVExOCEQvF2=	NWD3[YpwOjRiaB?=	MoPwSG1UVw>?	MoXyTWM2OD1yLkGyOUDPxE1?	MWiyNlI4PDN7OR?=
LN18	NEDRPINEgXSxdH;4bYMhSXO\|YYm=	NYi5TXNiOTByIN88US=>	NHjMUYczPCCq	NXflb\|lLTE2VTx?=	NVrj[o1jUUN3ME2wMlIyOCEQvF2=	NEKzXIwzOjJ5NEO5PS=>
LN443	M3fsbmN6fG:2b4jpZ{BCe3OjeR?=	NUK1boI1OTByIN88US=>	MX6yOEBp	NGO5UXBFVVOR	MXTJR\|UxRTBwMkKwJO69VQ>?	MlzGNlIzPzR\|OUm=
HF66	NX3Ob4duS3m2b4TvfIlkKEG\|c3H5	MYmxNFAh\|ryP	NXjsdZJ{OjRiaB?=	MVfEUXNQ	M3rZOmlEPTB;MD6yNlUh\|ryP	NHXF[ZIzOjJ5NEO5PS=>
HF2303	MnjDR5l1d3SxeHnjJGF{e2G7	Ml;0NVAxKM7:TR?=	NGfYUVgzPCCq	M1rGUWROW09?	M4npcGlEPTB;MD6wOlAh\|ryP	NXvPPGRzOjJ{N{SzPVk>
HF2359	Ml;1R5l1d3SxeHnjJGF{e2G7	NVOyOXBoOTByIN88US=>	NWXjSYlMOjRiaB?=	MVHEUXNQ	NYfnSJU5UUN3ME2wMlA3OCEQvF2=	NVnjOXMzOjJ{N{SzPVk>
HF2414	MkjaR5l1d3SxeHnjJGF{e2G7	M4OyNVExOCEQvF2=	MlvzNlQhcA>?	M{HmPGROW09?	NHvmNZBKSzVyPUCuNFgxKM7:TR?=	M3vJdVIzOjd2M{m5
A-673	NV3FN3duT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVuxNEDPxE1?	NHjDUZo6PiCq	Mo[wSG1UVw>?	MYDJR\|UxRTBwMEOyJO69VQ>?	Mk\ENlE1PDh3OUG=
TC-32	NHeyVnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn74NVAh\|ryP	NWTEPIFiQTZiaB?=	M{DPVmROW09?	NEXWV4ZKSzVyPUCuNFM6KM7:TR?=	MU[yNVQ1QDV7MR?=
TC-71	M3jtN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2LnWFExKM7:TR?=	NVr1Z3pEQTZiaB?=	M{S0SGROW09?	NHzvcWpKSzVyPUCuNVAzKM7:TR?=	MlXDNlE1PDh3OUG=
SK-N-MC	M1LCV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2jKSlExKM7:TR?=	M2PUOlk3KGh?	NHnodFlFVVOR	M{KwdGlEPTB;MD6wO\|Ih\|ryP	NX7z[HFiOjF2NEi1PVE>
CHLA-9	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmTuNVAh\|ryP	M2rrdlk3KGh?	NEL6PJhFVVOR	MVvJR\|UxRTBwMEG4JO69VQ>?	M{TmZVIyPDR6NUmx
CHLA-10	NV7nfm97T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEDWdpkyOCEQvF2=	NG\YUHo6PiCq	NXXq[nBpTE2VTx?=	NXfMfItzUUN3ME2wMlA3OCEQvF2=	NYXkcHRyOjF2NEi1PVE>
CHLA-25	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG\hTFYyOCEQvF2=	NFfrfIw6PiCq	MXfEUXNQ	M2C2UWlEPTB;MD6xOlgh\|ryP	NEXh[JYzOTR2OEW5NS=>
CHLA-32	M1fBbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYixZWtSOTBizszN	M2fISFk3KGh?	NXS5ZYt3TE2VTx?=	M2j0RWlEPTB;MD6xN\|Yh\|ryP	NHvX[GMzOTR2OEW5NS=>
CHLA-56	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmnyNVAh\|ryP	MmXWPVYhcA>?	NGHwPGhFVVOR	NWHETYVvUUN3ME2xNEDPxE1?	MkTMNlE1PDh3OUG=
CHLA-258	MmD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFz3b3IyOCEQvF2=	NX\FO5liQTZiaB?=	NETnSmhFVVOR	M1H0fWlEPTB;MD6xN\|Ih\|ryP	MVqyNVQ1QDV7MR?=
COG-E-352	NELpe5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVWxNEDPxE1?	NGjGUFU6PiCq	NUTrcGd3TE2VTx?=	M{P6PGlEPTB;MD6wOFMh\|ryP	M4nUSlIyPDR6NUmx
CHLA-90	M3rnNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M17zc\|ExKM7:TR?=	NFnhc5o6PiCq	NV65TmhbTE2VTx?=	NV3rfpdCUUN3ME2wMlA3OSEQvF2=	MW[yNVQ1QDV7MR?=
CHLA-119	MlvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIfFOZAyOCEQvF2=	MVW5OkBp	NFrX[G9FVVOR	NVPUfI46UUN3ME2wMlAzOiEQvF2=	NUTyPGZjOjF2NEi1PVE>
CHLA-122	NVH6ZnNXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1rvT\|ExKM7:TR?=	M3raWFk3KGh?	NXTz[ZdGTE2VTx?=	MXfJR\|UxRTBwMEG5JO69VQ>?	NEjPOW4zOTR2OEW5NS=>
CHLA-136	NVLXTWNqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnfLNVAh\|ryP	MlrVPVYhcA>?	MnrzSG1UVw>?	M4G1fWlEPTB;MD6wN\|kh\|ryP	NHzjXGgzOTR2OEW5NS=>
CHLA-140	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn3rNVAh\|ryP	M{PteFk3KGh?	NFLnSoFFVVOR	MlnMTWM2OD1yLkCyOkDPxE1?	Mk\ONlE1PDh3OUG=
LA-N-6	M17sdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml;wNVAh\|ryP	NH\nWFQ6PiCq	NUHFepd1TE2VTx?=	NViwcHd2UUN3ME2wMlA2PCEQvF2=	NEO1WVIzOTR2OEW5NS=>
NB-1643	NYPCeGZQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmW2NVAh\|ryP	MV[5OkBp	NHrJPZZFVVOR	MnW1TWM2OD1yLkCzO{DPxE1?	NHnMeXEzOTR2OEW5NS=>
NB-EBc1	NIj3dG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVKxNEDPxE1?	NGfkbmI6PiCq	MWLEUXNQ	NIXuSWNKSzVyPUCuNFUxKM7:TR?=	MmjxNlE1PDh3OUG=
SK-N-BE-1	NHjINVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkjyNVAh\|ryP	MVS5OkBp	Mmq2SG1UVw>?	Ml;PTWM2OD1yLkCyPEDPxE1?	NIC3cnozOTR2OEW5NS=>
SK-N-BE-2	NUjzPGpyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWrDSmxpOTBizszN	MWC5OkBp	Mli0SG1UVw>?	MVPJR\|UxRTBwMEO2JO69VQ>?	Mk\uNlE1PDh3OUG=
SMS-KAN	M2r2PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXyxNEDPxE1?	NV74RZBHQTZiaB?=	MX3EUXNQ	M3;POWlEPTB;MD6wN\|Qh\|ryP	M3vxOFIyPDR6NUmx
SMS-KANR	MlnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHfXd2UyOCEQvF2=	MoHLPVYhcA>?	MmnjSG1UVw>?	NFPydFNKSzVyPUCuNFI3KM7:TR?=	MWeyNVQ1QDV7MR?=
SMS-KCN	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV21VoxqOTBizszN	M4rwOlk3KGh?	Mk\3SG1UVw>?	MWrJR\|UxRTBwMEG5JO69VQ>?	MWSyNVQ1QDV7MR?=
SMS-KCNR	M2f0[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXyxNEDPxE1?	MnHxPVYhcA>?	MmPNSG1UVw>?	M4fx[mlEPTB;MD6wNVAh\|ryP	NIXNPHIzOTR2OEW5NS=>
SMS-LHN	NGDrN5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIXufZIyOCEQvF2=	NEXoSlg6PiCq	MYLEUXNQ	MmrQTWM2OD1yLkCzNkDPxE1?	NGjpVWkzOTR2OEW5NS=>
SMS-MSN	M3LJS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXjNZ\|RrOTBizszN	M3fDblk3KGh?	NXrJTlk4TE2VTx?=	M{\NPGlEPTB;MD6wNlIh\|ryP	MXqyNVQ1QDV7MR?=
SMS-SAN	M3f3Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXKxNEDPxE1?	MWi5OkBp	MWLEUXNQ	MUDJR\|UxRTBwMEKwJO69VQ>?	NFLrT3ozOTR2OEW5NS=>
Granta-4	M3LsVGN6fG:2b4jpZ{BCe3OjeR?=	M2XTcFExKM7:TR?=	NFjyfWU4KGR?		MlLVTWM2OD1yLkC0NEDPxE1?	NYrV[3VQOjF{OUG4Olc>
DB	Ml;ER5l1d3SxeHnjJGF{e2G7	MWGxNEDPxE1?	MUG3JIQ>		MX3JR\|UxRTBwMESyJO69VQ>?	MX2yNVI6OTh4Nx?=
RL	M1X2XGN6fG:2b4jpZ{BCe3OjeR?=	MmTnNVAh\|ryP	Mmr0O{Bl		MXjJR\|UxRTBwMEG1JO69VQ>?	M1vFXlIyOjlzOE[3
K562	NIDKT5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUOxNEDPxE1?	MlTmPVYhcA>?		NHXnVmNKSzVyPUCuNFg4KM7:TR?=	M3L3SVIyODlzNkOz
LAMA-84	NVP0V3c4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{fV[lExKM7:TR?=	NGf1OYY6PiCq		M{nrSmlEPTB;MD6wOVch\|ryP	NX\IVoZSOjFyOUG2N\|M>
MM15	M3zse2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHv1bVU1KM7:TR?=	NIrSNoI4OiCq	NIXpNmRFVVOR	MXrJR\|UxRTBwMUOg{txO	M3;pdVIxOzh{OES0
OPM1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmfUOEDPxE1?	NYjU[JY{PzJiaB?=	MUnEUXNQ	M3jLNmlEPTB;MD6wN{DPxE1?	MXSyNFM5Ojh2NB?=
RPM1	NYH0VVN5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4jqdlQh\|ryP	NYn2cYpwPzJiaB?=	M4SwT2ROW09?	NUDpdGUzUUN3ME2xNE4{OiEQvF2=	MV6yNFM5Ojh2NB?=
INA6	NGT3eItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYi0JO69VQ>?	NXL1cHJzPzJiaB?=	MoiySG1UVw>?	NEHZe5FKSzVyPUCuNFAzKM7:TR?=	MmXlNlA{QDJ6NES=
OPM2	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmjpOEDPxE1?	M1jSPVczKGh?	M3;mOGROW09?	MYXJR\|UxRTRwM{eg{txO	MkLXNlA{QDJ6NES=
MM1R	Mn\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVe0JO69VQ>?	MonBO\|IhcA>?	NXPyd2x{TE2VTx?=	NGnFd5dKSzVyPUGuOlgh\|ryP	MkPGNlA{QDJ6NES=
DOX40	M2LCVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn35OEDPxE1?	NYrBZlI3PzJiaB?=	MXPEUXNQ	MmfsTWM2OD13LkS4JO69VQ>?	MVeyNFM5Ojh2NB?=
LR5	M2LkVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3nCd\|Qh\|ryP	MlXDO\|IhcA>?	MoXHSG1UVw>?	M1ToZWlEPTB;Mj61N{DPxE1?	MWmyNFM5Ojh2NB?=
U266	NXvpRWFKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoHVOEDPxE1?	M2r0flczKGh?	MWPEUXNQ	M1v4ZmlEPTB;MT60N{DPxE1?	NVi2eVlFOjB\|OEK4OFQ>
RD	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFrJe5EyOCEQvF2=	MlL0PVYhcA>?		M1PmXmlEPTB;MD6yNlgh\|ryP	MmfXNlAyODh\|M{i=
Rh41	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV25epBUOTBizszN	MnTsPVYhcA>?		M4PPdWlEPTB;MD6wPVAh\|ryP	MX6yNFExQDN\|OB?=
Rh30	Mlz2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmH3NVAh\|ryP	MlXFPVYhcA>?		M3H3cmlEPTB;MD6yN\|Ah\|ryP	Mn;rNlAyODh\|M{i=
BT-12	NIG3ToZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX35RoZuOTBizszN	MVW5OkBp		MVvJR\|UxRTBwME[wJO69VQ>?	NGPvXmszODFyOEOzPC=>
CHLA-266	NET6SHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3yweFExKM7:TR?=	MkjDPVYhcA>?		NIGze4NKSzVyPUCuNFczKM7:TR?=	NV3wcoFMOjBzMEizN\|g>
TC-71	NYi5bI5ET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX6xNEDPxE1?	NVSwNmxrQTZiaB?=		NXrxeJg3UUN3ME2wMlExOiEQvF2=	MoTPNlAyODh\|M{i=
SJ-GBM2	NVjMd2ZKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkS3NVAh\|ryP	MmrOPVYhcA>?		NV;NN25oUUN3ME2wMlA2OCEQvF2=	MknwNlAyODh\|M{i=
NALM-6	MkS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFX5W5kyOCEQvF2=	MXe5OkBp		M1LEWGlEPTB;MD6wOlIh\|ryP	NYribINQOjBzMEizN\|g>
COG-LL-317	M1fCb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGC3VXIyOCEQvF2=	NYqw[W92QTZiaB?=		NIq1OoZKSzVyPUCuNFQ4KM7:TR?=	NXvSToZ[OjBzMEizN\|g>
RS4-11	MlXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NETyRXIyOCEQvF2=	NF;3ZYs6PiCq		NILKTmhKSzVyPUCuNFE5KM7:TR?=	MkKzNlAyODh\|M{i=
MOLT-4	NXz0PXJlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NW\FPXlzOTBizszN	NUKxZ4x2QTZiaB?=		NH3FPXhKSzVyPUCuNFI3KM7:TR?=	M2HqWFIxOTB6M{O4
CCRF-CEM	NFXBb5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmfLNVAh\|ryP	M3XSfFk3KGh?		M4jj[2lEPTB;MD6wPVQh\|ryP	MXeyNFExQDN\|OB?=
Kasumi-1	NEDDV4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1\uN\|ExKM7:TR?=	M3PPTlk3KGh?		NFXmZmRKSzVyPUCuNVA{KM7:TR?=	MmXsNlAyODh\|M{i=
Karpas-299	NGPUTotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX;BZpFIOTBizszN	MkPwPVYhcA>?		M1Tqe2lEPTB;MD6wN\|gh\|ryP	MofKNlAyODh\|M{i=
Ramos-RA1	MkTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3mzPFExKM7:TR?=	NIjheYs6PiCq		M37yPGlEPTB;MD6xNlch\|ryP	NG[xTXEzODFyOEOzPC=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-AURKA(T288) / p-EIF4E(S209) / c-Myc; PubMed: 28073841 Clin Cancer Res Inhibition of AURKA with alisertib downregulated p-EIF4E (S209) and c-MYC protein levels as assayed by Western blotting. phospho-Aurora A / Aurora B; PubMed: 22863010 Cell MLN8237differentially inhibited phosphorylation of Aurora kinases. CMK cells were incubated with 0.1 µM paclitaxel for 18 hr, then DMSO or MLN8237 was added and incubated for 2 hr. The degree of phosphorylation of the Aurora kinases in each sample was determined by Western blot. H3S10P / H3K27me2 / H3K27me3 / H3K9me2 / H3AcK / H4K16Ac; PubMed: 29477140 Mol Cells THP-1 cells were treated with alisertib or DMSO for 48 h. The levels of histone modifications were detected by western blot analysis with the indicated antibodies. H3 was used as a loading control.	28073841 22863010 29477140
Growth inhibition assay	Cell viability; PubMed: 25632225 Drug Des Devel Ther PANC-1 and BxPC-3 cells were treated with ALS at concentrations ranging from 0.1 μM to 50 μM for 24 hours. The viability of PANC-1 and BxPC-3 cells determined by MTT assay. ALS, alisertib.	25632225
Immunofluorescence	acetylated α-tubulin / γ-tubulin; PubMed: 29401581 FASEB J Representative immunofluorescence (IF) image and graph in human PKD1-mutant WT9-7, WT9-12 cells or hTERT-RPE1 (RPE1) cells after 2 hours treatment with vehicle, ganetespib , or alisertib to inhibit AURKA, or combination of alisertib and ganetespib. acetylated α-tubulin (red); γ-tubulin (green); DAPI (blue). Scale bars, 5 μm. E-cadherin / β-catenin / vimentin / p-SMAD5; PubMed: 23334326 Oncogene Immunofluorescence analysis of CD24 (-/low) cells treated with1 μM MLN8237 for 48 and 72 h showing reversion of EMT. E-cadherin and p-SMAD5 were labeled in red, β-catenin and vimentin were labeled in green, and DNA was labeled in blue with Hoechst dye. Centrin-2 / tubulin; PubMed: 30899434 Oncotarget Following inhibition of Aurora A kinase activity with 100 nM alisertib, cells with two or excess centrosomes similarly exhibit disorganized mitotic spindles. Cells with extra centrosomes are efficiently clustered into bipolar spindles prior to anaphase onset while those with supernumerary centrosomes undergo multipolar mitoses. Centrin-2, a marker of centrioles is shown in green, tubulin in red, and chromatin in blue. AurA inhibitor: alisertib. phospho-Aurora A(T288); PubMed: 20382844 Blood MM1.S cells were treated with DMSO or MLN8237 (0.5μM) for 24 hours and then stained with anti-phospho (Thr288)-Aurora-A kinase antibody (red), αtubulin (green), and DNA (blue). Overlapping localization is shown in the merged images. Arrow indicates Aurora-A autophosphorylation on Thr288 in the centrosome (original magnification ×40). Magnified single mitotic cell image is shown in the right panel.	29401581 23334326 30899434 20382844

In vivo

MLN8237 significantly reduces the tumor burden with tumor growth inhibition (TGI) of 42% and 80% at 15 mg/kg and 30 mg/kg, respectively, and prolongs the survival of mice compared with the control. ^[2]

Protocol

Kinase Assay:^[1]	+ Expand Aurora A radioactive Flashplate enzyme assay: Aurora A radioactive Flashplate enzyme assay is conducted to determine the nature and degree of MLN8237-mediated inhibition in vitro. Recombinant Aurora A is expressed in Sf9 cells and purified with GST affinity chromatography. The peptide substrate for Aurora A is conjugated with biotin (Biotin-GLRRASLG). Aurora A kinase (5 nM) is assayed in 50 mM Hepes (pH 7.5), 10 mM MgCl₂, 5 mM DTT, 0.05% Tween 20, 2 μM peptide substrate, 3.3 μCi/mL [γ-³³P]ATP at 2 μM, and increasing concentrations of MLN8237 by using Image FlashPlates.
Cell Research:^[2]	+ Expand Cell lines: MM1.S, MM.1R, LR5, RPMI 8226, DOX40, OPM1, OPM2, INA6, and U266 Concentrations: Dissolved in DMSO, final concentrations ~10 μM Incubation Time: 24, 48, and 72 hours Method: Cells are exposed to various concentrations of MLN8237 for 24, 48, and 72 hours. Cells viability is measured using MTT assay, and cell proliferation is measured using ³[H]-thymidine incorporation. For cell cycle analysis, cells are permeabilized by 70% ethanol at -20 °C, and incubated with 50 μg/mL PI and 20 units/mL RNase-A. DNA content is analyzed by flow cytometry using BDFACS-Canto II and FlowJo software. For the detection of apoptosis and senescence, cells are stained with fluorescein isothiocyanate-annexin V and PI. Apoptotic cells are determined by flow cytometric analysis using BDFACS-Canto II and FlowJo software. (Only for Reference)
Animal Research:^[2]	+ Expand Animal Models: Severe combined immune-deficient (SCID) mice inoculated subcutaneously with MM1.S cells Formulation: Formulated in 10% 2-hydroxypropyl-β-cyclodextrin/1% sodium bicarbonate Dosages: ~30 mg/kg/day Administration: Orally (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	27 mg/mL (52.03 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5%DMSO+30% PEG300+5%Tween-80+ddH2O For best results, use promptly after mixing.	8mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Alisertib (MLN8237) SDF

Molecular Weight	518.92
Formula	C₂₇H₂₀ClFN₄O₄
CAS No.	1028486-01-2
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02860000	Recruiting	Estrogen Receptor Status\|HER2/Neu Negative\|Invasive Breast Carcinoma\|Postmenopausal\|Stage III Breast Cancer\|Stage IIIA Breast Cancer\|Stage IIIB Breast Cancer\|Stage IIIC Breast Cancer\|Stage IV Breast Cancer	Mayo Clinic\|National Cancer Institute (NCI)	July 6 2017	Phase 2
NCT02860000	Recruiting	Estrogen Receptor Status\|HER2/Neu Negative\|Invasive Breast Carcinoma\|Postmenopausal\|Stage III Breast Cancer\|Stage IIIA Breast Cancer\|Stage IIIB Breast Cancer\|Stage IIIC Breast Cancer\|Stage IV Breast Cancer	Mayo Clinic\|National Cancer Institute (NCI)	July 6 2017	Phase 2
NCT02700022	Terminated	Diffuse Large B-cell Lymphoma\|Follicular Lymphoma\|Burkitt Lymphoma	UNC Lineberger Comprehensive Cancer Center\|Millennium Pharmaceuticals Inc.	October 2016	Phase 1
NCT02700022	Terminated	Diffuse Large B-cell Lymphoma\|Follicular Lymphoma\|Burkitt Lymphoma	UNC Lineberger Comprehensive Cancer Center\|Millennium Pharmaceuticals Inc.	October 2016	Phase 1
NCT02812056	Withdrawn	Malignant Neoplasms of Digestive Organs\|Malignant Neoplasms of Female Genital Organs\|Malignant Neoplasms of Lip Oral Cavity and Pharynx\|Malignant Neoplasms of Male Genital Organs	M.D. Anderson Cancer Center\|Millennium Pharmaceuticals Inc.	September 2016	Phase 1
NCT02812056	Withdrawn	Malignant Neoplasms of Digestive Organs\|Malignant Neoplasms of Female Genital Organs\|Malignant Neoplasms of Lip Oral Cavity and Pharynx\|Malignant Neoplasms of Male Genital Organs	M.D. Anderson Cancer Center\|Millennium Pharmaceuticals Inc.	September 2016	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What is the suggested formulation of this compound for mouse injection(i.p.)?
Answer:
It can be dissolved in 6% DMSO/50% PEG 300/5% Tween 80/ddH2O at 10 mg/ml as a clear solution.

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

Pan Aurora Kinase Inhibitor

Danusertib (PHA-739358) : Pan-Aurora kinase inhibitor, Aurora A/B/C, IC50=13 nM/79 nM/61 nM.
Pan Aurora Kinase Inhibitor

SNS-314 Mesylate : Pan-Aurora kinase inhibitor, Aurora A/B/C, IC50=9 nM/31 nM/3 nM.
Most Potent Aurora Kinase Inhibitor

MK-5108 (VX-689) : Aurora A, IC50=0.064 nM.
Aurora Kinase Inhibitor in Clinical Trial

VX-680 (Tozasertib, MK-0457) : Phase II for Advanced Non-Small Cell Lung Cancer (NSCLC).
Classic Aurora Kinase Inhibitor

Hesperadin : Potently inhibits Aurora B with IC50 of 250 nM.

Related Aurora Kinase Products5

Ro-3306 ^New

RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with K_i of 20 nM, >15-fold selectivity against a diverse panel of human kinases.
CCG-1423 ^New

CCG-1423 is a specific RhoA pathway inhibitor, which inhibits SRF-mediated transcription.
ML141 ^New

ML141 (CID-2950007), is demonstrated to be a potent, selective and reversible non-competitive inhibitor of Cdc42 GTPase suitable for in vitro assays, with IC50 of 200 nM and selectivity against other members of the Rho family of GTPases (Rac1, Rab2, Rab7).
Barasertib (AZD1152-HQPA|AZD2811)

Barasertib (AZD1152-HQPA) is a highly selective Aurora B inhibitor with IC50 of 0.37 nM in a cell-free assay, ~3700 fold more selective for Aurora B over Aurora A. Phase 1.
Tozasertib (VX-680, MK-0457)

Tozasertib (VX-680, MK-0457) is a pan-Aurora inhibitor, mostly against Aurora A with K_i_app of 0.6 nM in a cell-free assay, less potent towards Aurora B/Aurora C and 100-fold more selective for Aurora A than 55 other kinases. Phase 2.
Danusertib (PHA-739358)

Danusertib (PHA-739358) is an Aurora kinase inhibitor for Aurora A/B/C with IC50 of 13 nM/79 nM/61 nM in cell-free assays, modestly potent to Abl, TrkA, c-RET and FGFR1, and less potent to Lck, VEGFR2/3, c-Kit, CDK2, etc. Phase 2.
ZM 447439

ZM 447439 is a selective and ATP-competitive inhibitor for Aurora A and Aurora B with IC50 of 110 nM and 130 nM, respectively. It is more than 8-fold selective for Aurora A/B than MEK1, Src, Lck and has little effect against CDK1/2/4, Plk1, Chk1, etc.

Features:An Aurora selective ATP-competitive inhibitor.
MLN8054

MLN8054 is a potent and selective inhibitor of Aurora A with IC50 of 4 nM in Sf9 insect cell. It is more than 40-fold selective for Aurora A than Aurora B. Phase 1.
MK-5108 (VX-689)

MK-5108 (VX-689) is a highly selective Aurora A inhibitor with IC50 of 0.064 nM in a cell-free assay and is 220- and 190-fold more selective for Aurora A than Aurora B/C, while it inhibits TrkA with less than 100-fold selectivity. Phase 1.
Aurora A Inhibitor I (TC-S 7010)

Aurora A Inhibitor I is a novel, potent, and selective inhibitor of Aurora A with IC50 of 3.4 nM in a cell-free assay. It is 1000-fold more selective for Aurora A than Aurora B.

Features:Aurora A Inhibitor I is a novel, potent, and selective inhibitor to Aurora A.

Choose Your Country or Region

By Signaling Pathways

By product type

Alisertib (MLN8237)

Cited by 68 Publications

Purity & Quality Control

Choose Selective Aurora Kinase Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Alisertib (MLN8237) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

Related Aurora Kinase Products5

Choose Your Country or Region

By Signaling Pathways

By product type

Alisertib (MLN8237)

Cited by 68 Publications

Purity & Quality Control

Choose Selective Aurora Kinase Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Alisertib (MLN8237) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

Related Aurora Kinase Products5

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)